Intrexon bets $26M on stem cells, teams up with troubled OvaScience

Intrexon ($XON), a Maryland biotech backed by billionaire RJ Kirk, has agreed to snap up a San Diego regenerative medicine outfit for $26 million, and the company inked a separate agreement with OvaScience ($OVAS) to combine their technology platforms. In its buyout of Medistem, Intrexon will acquire blood vessel-forming stem cell technology with applications in cancer, wound healing, and cardiovascular disease, the company said, fueling some early-stage development projects. With OvaScience, a biotech still recovering from some FDA scorn, Intrexon is launching a joint venture called OvaXon that unites the duo's development platforms for human and animal fertility treatments. Medistem | OvaScience